News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • UnitedHealth beat Q3, Optum margins expanded to 5.6%, and company raised 2026 EPS guidance to at least $20.50.
  • Analyst recommends a long UNH trade: entry near $419.29, stop $385.00, target $480.00 on a 180-trading-day horizon.
  • Sanofi trades near its 52-week low while Dupixent growth accelerates and the stock yields about 4.5%.
  • Analyst calls SNY a buy-the-dip with entry $41.00, target $46.00, stop $38.50 over roughly 45 trading days.
  • Insurer margin recovery and pharma dividend appeal support risk-on flows into large-cap healthcare stocks.

Latest Articles

U.S. Diesel Climbs to Record amid Escalating Supply Disruptions

U.S. Diesel Climbs to Record amid Escalating Supply Disruptions

U.S. diesel prices reached an intraday record, driven by supply squeezes after renewed hostilities involving the U.S. and Iran and disruptions from attacks on Russian refineries. Inventories are at multi-decade lows, refiners are running at high rates, and seasonal demand risks pushing costs higher for trucking, agriculture and heating.

Oura Seeks Nasdaq Listing After Rapid Revenue and Membership Gains

Oura Seeks Nasdaq Listing After Rapid Revenue and Membership Gains

ŌURA Inc. has submitted a Form S-1 registration with the SEC for an initial public offering, applying to list on the Nasdaq Global Select Market under the ticker OURA. The San Francisco company reported sharply higher revenue, expanding profitability and a doubling of paid memberships over the last year, while financial terms for the offering remai…

Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS

Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS

Cytek Biosciences highlights its expanding role in clinical research through spectral flow cytometry at the 2026 ESCCA and ICCS conferences. The company will demonstrate its Full Spectrum Profiling (FSP) technology, which enhances cell analysis capabilities and workflow efficiency. Presentations and workshops will focus on innovative applications i…

Root to Participate in Upcoming Investor Conferences

Root to Participate in Upcoming Investor Conferences

Root, Inc., a leading technology company in car insurance, announced its participation in the upcoming KBW Insurance Conference and Goldman Sachs Americas Financial Technology Conference. The company will engage in one-on-one and group meetings with institutional investors but will not hold a general presentation. Investor materials are available o…

Weatherford Shareholders Approve Redomestication to Delaware

Weatherford Shareholders Approve Redomestication to Delaware

Weatherford International plc announced shareholder approval to redomesticate from Ireland to Delaware, aiming to streamline its corporate structure, align better with global operations, and achieve $20–30 million in annual cash savings starting in 2027. The move is expected to enhance financial flexibility and support long-term value creation, sub…

Globus Medical Announces CE Mark for Excelsius3D™ Imaging System

Globus Medical Announces CE Mark for Excelsius3D™ Imaging System

Globus Medical announced that its Excelsius3D intelligent 3-in-1 imaging system has received CE Mark approval for commercial sale within the European Union and the United Kingdom. This marks a significant expansion of the company's Excelsius Ecosystem, enhancing surgical workflows by integrating advanced intraoperative imaging with robotic navigati…

FingerMotion Announces Non-Binding Three-Party MOU with Lyken.AI and BlueFlare and Provides Update on Alberta Corridor Gas-Supply Discussions

FingerMotion Announces Non-Binding Three-Party MOU with Lyken.AI and BlueFlare and Provides Update on Alberta Corridor Gas-Supply Discussions

FingerMotion, Inc. entered a non-binding memorandum of understanding with Lyken AI Computing and BlueFlare Energy to create a demand-to-capacity matching framework for AI and HPC enterprise workloads in Western Canada, focusing on Alberta corridor sites. The company also provided updates on ongoing natural gas supply discussions supporting behind-t…

Quanex Building Products Announces Third Quarter 2026 Results

Quanex Building Products Announces Third Quarter 2026 Results

Quanex Building Products Corporation announced its financial results for Q3 2026, reporting net sales growth to $501.8 million, margin improvements particularly in the Hardware Solutions segment, and repayment of $42.25 million in debt. Adjusted EBITDA increased to $72.7 million, highlighting operational progress despite macroeconomic inflation pre…

Lianhe Sowell International Group Ltd. Announces Closing of an $11 Million Best-efforts Follow-on Public Offering

Lianhe Sowell International Group Ltd. Announces Closing of an $11 Million Best-efforts Follow-on Public Offering

Lianhe Sowell International Group Ltd., a Nasdaq-listed provider of industrial machine vision products and solutions in China, has successfully completed a best-efforts follow-on public offering, raising approximately $11 million. The offering included units composed of Class A Ordinary Shares and warrants. Proceeds from the offering will be used p…

Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Latigo Biotherapeutics announced its second quarter 2026 results along with key business milestones including an upsized IPO that raised $397.4 million gross proceeds, publication of positive Phase 2 trial results of onzotrigine in The New England Journal of Medicine, and initiation of Phase 3 clinical trials. The company also appointed Naomi Lowy,…